Mumbai, Feb. 26 -- According to an exchange filing, the inspection was conducted at the company's Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.

The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company's consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.4...